Pharmacological Evaluation of Antiasthmatic Activity of Myrica nagi Bark Extracts
Related Experiment Video
Updated: Mar 14, 2026
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
Published on: July 10, 2018
1Department of Pharmacognosy, Laureate Institute of Pharmacy, Kathog, Kangra, H. P., India, P.O. Box: 177101.. India.
Background:
The involvement of debilitating side effects of allopathic antiasthmatic drugs provides a strong impetus for the development of new herbal therapeutics. Myrica nagi Thunb. (Syn. Kaiphal) of Myricaceae family is a known drug of the Ayurveda system used for the treatment of several diseases including asthma.
Methods:
The present study deals with the preparation and phytochemical screening of polar, non-polar and methanolic extracts of Myrica nagi bark followed by the evaluation of their antiasthmatic activity using four different animal experimental models: acetylcholine induced bronchospasm in conscious guinea pigs, acetylcholine induced contraction on isolated guinea pig tracheal chain preparation, compound 48/80 induced mast cell degranulation using rat, and trypsin and egg albumin induced bronchospasm in conscious rat.
Results:
Polar extract of M. nagi bark (200 mg/kg, p.o.) exerted strong antiasthmatic effects near to Ketotifen (1 mg/kg, p.o) as standard drug. Polar extract of M. nagi bark (200 µ.g/ml) significantly inhibited Ach induced contraction of isolated guinea pig tracheal chain preparation. Pre-incubation of rat peritoneal mast cells with test drugs (methanolic, non polar and polar extracts) showed dose dependent significant reduction of % mast cell degranulation. Polar extract (200mg/kg) & Methanolic extract (200mg/kg) of M. nagi bark treated animals showed significantly lesser serum bicarbonate level, higher tidal volume, lower level of eosinophils and neutrophils.
Conclusion:
The results of present investigation suggest that the polar extracts of Myrica nagi bark have better antiasthmatic activity than the non polar and methanolic extract.
Related Concept Videos
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...